Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
Sponsor: Pfizer
Listed as NCT05238311, this observational or N/A phase trial focuses on Multiple Myeloma and remains ongoing. Sponsored by Pfizer, it has been updated 10 times since 2026, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Mar 2025 — Present [monthly]
No Longer Available
Status: Temporarily Not Available → No Longer Available
-
Sep 2024 — Mar 2025 [monthly]
Temporarily Not Available
Status: Available → Temporarily Not Available
-
Jul 2024 — Sep 2024 [monthly]
Available
-
Jun 2024 — Jul 2024 [monthly]
Available
Status: Temporarily Not Available → Available
-
Dec 2023 — Jun 2024 [monthly]
Temporarily Not Available
▶ Show 5 earlier versions
-
Nov 2023 — Dec 2023 [monthly]
Temporarily Not Available
Status: Available → Temporarily Not Available
-
Jul 2023 — Nov 2023 [monthly]
Available
Status: Temporarily Not Available → Available
-
May 2023 — Jul 2023 [monthly]
Temporarily Not Available
Status: Available → Temporarily Not Available
-
Mar 2023 — May 2023 [monthly]
Available
-
Mar 2022 — Mar 2023 [monthly]
Available
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.